TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16879301

Group type: EXPERIMENTAL
Intervention: MBP8298 (500 mg administered intravenously every 6 months)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 32
Study: 12556915

Group type: EXPERIMENTAL
Intervention: Clozapine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 11109308

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (Asmag, Magne B6)
Number of subjects: 0
Study: 8924575

Group type: EXPERIMENTAL
Intervention: Erythropoietin pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 1292788

Group type: EXPERIMENTAL
Intervention: Iliac perfusion with melphalan
Number of subjects: 117

Group type: COMPARATOR
Intervention: Femoral perfusion with melphalan
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Iliac perfusion
Number of subjects: 117

Group type: COMPARATOR
Intervention: Femoral perfusion
Number of subjects: 117
Study: 6721284

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31793731

Group type: EXPERIMENTAL
Intervention: S. alopecuroides extract (400 mg capsules, once daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31125614

Group type: EXPERIMENTAL
Intervention: Baseline continuous variables from 13 RCTs
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Baseline categorical variables from 13 RCTs
Number of subjects: 13

Group type: COMPARATOR
Intervention: Baseline continuous variables from RCTs with fabricated data
Number of subjects: 13

Group type: COMPARATOR
Intervention: Baseline categorical variables from RCTs with fabricated data
Number of subjects: 13

Group type: COMPARATOR
Intervention: Baseline P values from genuine RCTs
Number of subjects: 13
Study: 27614318

Group type: EXPERIMENTAL
Intervention: Lubricin (150 μg/mL) eye drops
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sodium Hyaluronate (HA) 0.18% eye drops
Number of subjects: 39
Study: 24746942

Group type: EXPERIMENTAL
Intervention: Beclometasone/formoterol (200 μg/24 μg for children; 400 μg/24 μg for adolescents and adults) via pMDI with AeroChamber Plus™
Number of subjects: 73

Group type: COMPARATOR
Intervention: Beclometasone/formoterol (400 μg/24 μg) via pMDI with AeroChamber Plus™
Number of subjects: 73
Study: 23688206

Group type: EXPERIMENTAL
Intervention: Acoustic Wave Therapy (AWT(®)), treated once a week for 7 weeks, total of 8 treatments
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 21400543

Group type: EXPERIMENTAL
Intervention: Multivessel revascularization (MVR)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Single-vessel revascularization (SVR)
Number of subjects: 366
Study: 20074465

Group type: EXPERIMENTAL
Intervention: 1 percent chlorhexidine gel (TG)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (CG; n=10)
Number of subjects: 25
Study: 17453284

Group type: EXPERIMENTAL
Intervention: Posterior fundoplication (PF)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Anterior fundoplication (AF)
Number of subjects: 95
Study: 15120931

Group type: EXPERIMENTAL
Intervention: Iseganan 9mg oral rinse, swished/swallowed six times daily for up to 21 days.
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo oral rinse, swished/swallowed six times daily for up to 21 days.
Number of subjects: 502
Study: 11584757

Group type: EXPERIMENTAL
Intervention: Ivermectin + ferrous sulphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ferrous sulphate alone
Number of subjects: 0
Study: 9783307

Group type: EXPERIMENTAL
Intervention: rHuEpo subcutaneously, 900 U/kg week‐1, 3 times weekly, supplemented with iron and vitamin E
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (116 preterm infants of the same gestational age, admitted to the Neonatal Intensive Care Unit from 1 January 1992 to 31 December 1992)
Number of subjects: 107
Study: 8150104

Group type: EXPERIMENTAL
Intervention: 5,000 IU hCG
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 26
Study: 3152400

Group type: EXPERIMENTAL
Intervention: FM sonography
Number of subjects: 55

Group type: COMPARATOR
Intervention: AM sonography
Number of subjects: 55

Group type: COMPARATOR
Intervention: FM sonography and AM sonography
Number of subjects: 55
Study: 31162663

Group type: EXPERIMENTAL
Intervention: Total Extraperitoneal (TEP) repair
Number of subjects: 416

Group type: COMPARATOR
Intervention: Lichtenstein repair
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Both TEP and Lichtenstein
Number of subjects: 416
Study: 28360244

Group type: EXPERIMENTAL
Intervention: ACP-led clinic for severe SDB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician-led care for severe SDB
Number of subjects: 0
Study: 25113527

Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg nightly for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single dose of a serotonin 2A receptor antagonist
Number of subjects: 40
Study: 23143523

Group type: EXPERIMENTAL
Intervention: Long acting injectable (LAI) risperidone
Number of subjects: 446

Group type: COMPARATOR
Intervention: Oral antipsychotic medications
Number of subjects: 446
Study: 21366472

Group type: EXPERIMENTAL
Intervention: Bolus administration of furosemide every 12 hours
Number of subjects: 308

Group type: COMPARATOR
Intervention: Continuous infusion of furosemide
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: High-dose furosemide (2.5 times previous oral dose)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Low-dose furosemide (equivalent to previous oral dose)
Number of subjects: 308
Study: 18651551

Group type: EXPERIMENTAL
Intervention: EBPG-based computerised clinical decision support (CDS) system
Number of subjects: 739

Group type: COMPARATOR
Intervention: No access to EBPG-based computerised clinical decision support (CDS) system
Number of subjects: 739
Study: 17046323

Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation (AF)
Number of subjects: 55106

Group type: COMPARATOR
Intervention: Sinus Rhythm (SR)
Number of subjects: 55106

Group type: COMPARATOR
Intervention: Restrictive filling pattern
Number of subjects: 55106
Study: 15130192

Group type: EXPERIMENTAL
Intervention: Competitive condition
Number of subjects: 52

Group type: COMPARATOR
Intervention: Non-competitive condition
Number of subjects: 52
Study: 10933269

Group type: EXPERIMENTAL
Intervention: Passive smoking
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Active smoking
Number of subjects: 177
Study: 9347277

Group type: EXPERIMENTAL
Intervention: Propafenone (450 to 750 mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 7504134

Group type: EXPERIMENTAL
Intervention: Doxazosin (10.3 ± 6.3 mg/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (44.0 ± 11.0 mg/day)
Number of subjects: 48
Study: 3550034

Group type: EXPERIMENTAL
Intervention: Subgingival scaling and root planing under local anesthesia
Number of subjects: 47

Group type: COMPARATOR
Intervention: Occlusal adjustment
Number of subjects: 47
Study: 30462162

Group type: EXPERIMENTAL
Intervention: Exercise program alone
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Combined-exercise program and nutrition supplement
Number of subjects: 113

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 113
Study: 29326030

Group type: EXPERIMENTAL
Intervention: ADT plus abiraterone acetate (1000 mg) and prednisone (5 mg) once daily
Number of subjects: 1199

Group type: COMPARATOR
Intervention: ADT plus placebos
Number of subjects: 1199
Study: 26730644

Group type: EXPERIMENTAL
Intervention: Hypothesis-driven teaching curriculum for pulmonary fellows
Number of subjects: 0

Group type: COMPARATOR
Intervention: Head-to-toe examination instruction for pulmonary fellows
Number of subjects: 0
Study: 24559816

Group type: EXPERIMENTAL
Intervention: Sedative music intervention (soft, instrumental slow music, 60-80 beats per minute, 40 minutes duration, for 6 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Overall comparison at week 6
Number of subjects: 60
Study: 22516862

Group type: EXPERIMENTAL
Intervention: Intervention targeting fathers
Number of subjects: 50
Study: 20568023

Group type: EXPERIMENTAL
Intervention: Conivaptan 20 mg IV as a bolus followed by 20 mg IV over 24 h
Number of subjects: 6

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6
Study: 17566112

Group type: EXPERIMENTAL
Intervention: PYY(1-36)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PYY(3-36)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study: 16032449

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 30
Study: 12124866

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: 100 mg oral prasterone
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: 200 mg oral prasterone
Number of subjects: 191
Study: 10574618

Group type: EXPERIMENTAL
Intervention: IFN-beta1b (8 million international units, subcutaneous)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: IFN-beta1a (6 million international units, intramuscular)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study: 10163462

Group type: EXPERIMENTAL
Intervention: Antioxidant micronutrients and trace minerals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 0
Study: 1827021

Group type: EXPERIMENTAL
Intervention: Isradipine (7.9 +/- 3.5 mg/day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Atenolol (69.2 +/- 43.5 mg/day)
Number of subjects: 26
Study: 6927820

Group type: EXPERIMENTAL
Intervention: Ergocycle exercise at 55% of VO2 max for 20 minutes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ergocycle exercise at 70% of VO2 max for 20 minutes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ergocycle exercise at 85% of VO2 max for 20 minutes
Number of subjects: 8
Study: 31757691

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injections (IAIs) 2 mg every 4 weeks for the first 6 months, followed by 2 mg every 8 weeks.
Number of subjects: 31
Study: 29574394

Group type: EXPERIMENTAL
Intervention: Blended learning intervention (face-to-face tutorial + online clinical supervisee skills training app)
Number of subjects: 122
Study: 28255094

Group type: EXPERIMENTAL
Intervention: Face-to-face motivational interviewing (MI) combined with a self-instruction booklet (W) and follow-up telephone booster sessions (B; MI+W+B)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Face-to-face cognitive-behavioural therapy (CBT)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Postcare text messaging (9 months)
Number of subjects: 300
Study: 26729009

Group type: EXPERIMENTAL
Intervention: Concise cognitive behavioural therapy and/or pharmacotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 23307554

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled analyses of total cohort
Number of subjects: 0
Study: 21637131

Group type: EXPERIMENTAL
Intervention: MFGM-enriched complementary food (40 g/day)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Control group (skim milk proteins)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: MFGM-enriched complementary food
Number of subjects: 550
Study: 18293165

Group type: EXPERIMENTAL
Intervention: Test lovastatin generic (LVSG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Reference (mevinacor 40 MSD)
Number of subjects: 36
Study: 16213630

Group type: EXPERIMENTAL
Intervention: Baseline QEEG features
Number of subjects: 44
Study: 12505243

Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental treatment after disease progression or relapse
Number of subjects: 0
Study: 9860474

Group type: EXPERIMENTAL
Intervention: Adjuvant hepatic arterial infusion (HAI) of 5-fluorouracil (5-FU) 1000 mg/m2 per day for 5 days plus folinic acid 200 mg/m2 per day for 5 days
Number of subjects: 226

Group type: COMPARATOR
Intervention: Liver resection only (Control)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Adjuvant hepatic arterial infusion (HAI) of 5-FU
Number of subjects: 226
Study: 7623373

Group type: EXPERIMENTAL
Intervention: 1600 Kcal/day diet (group A)
Number of subjects: 217

Group type: COMPARATOR
Intervention: 2100 Kcal/day diet (group B)
Number of subjects: 217
Study: 2375249

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid 200 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid 400 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Paracetamol 500 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Paracetamol 1000 mg
Number of subjects: 70
Study: 1062275

Group type: EXPERIMENTAL
Intervention: Ultracain 4%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Xylocain 2%
Number of subjects: 0
Study: 7303702

Group type: EXPERIMENTAL
Intervention: Nova T
Number of subjects: 93

Group type: COMPARATOR
Intervention: Copper-T-200 Ag
Number of subjects: 93
Study: 30994603

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-molecular-weight heparins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants
Number of subjects: 0
Study: 29611892

Group type: EXPERIMENTAL
Intervention: MLC901 (0.8 g capsules 3 times daily)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 26348032

Group type: EXPERIMENTAL
Intervention: Skills of Cognitive Therapy (SoCT-IO) rated by independent observers
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Skills of Cognitive Therapy (SoCT-IO) ratings
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SoCT-IO ratings
Number of subjects: 80
Study: 25272643

Group type: EXPERIMENTAL
Intervention: Stannous chloride dihydrate at concentrations of 200, 400, 600, and 800 microg, followed by intravenous administration of 99mTc at 30 min intervals in group one.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Constant concentration of 400 microg of Sn PYP, followed by administration of 99mTc at different time intervals (15, 30, 60, and 120 min) in group two.
Number of subjects: 24
Study: 22403202

Group type: EXPERIMENTAL
Intervention: Health coaching by nonclinician personnel
Number of subjects: 0
Study: 19019903

Group type: EXPERIMENTAL
Intervention: After-school physical activity interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: After-school programmes
Number of subjects: 0
Study: 18235411

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of thoracic irradiation and chemotherapy (platinum salts and etoposide)
Number of subjects: 0
Study: 16298885

Group type: EXPERIMENTAL
Intervention: Free recall condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exogenous cueing condition with SOA of 150 ms
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exogenous cueing condition with SOA of 450 ms
Number of subjects: 40

Group type: COMPARATOR
Intervention: Exogenous cueing condition
Number of subjects: 40
Study: 12406041

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg t.i.d.)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study: 10443654

Group type: EXPERIMENTAL
Intervention: Testosterone patch
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study: 7569587

Group type: EXPERIMENTAL
Intervention: HRT (oral or non-oral 17-beta estradiol at skeletally protective dose)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study: 2161302

Group type: EXPERIMENTAL
Intervention: Itraconazole (100 mg once daily) for 30 days in dermatophytosis
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Itraconazole (100 mg once daily) for 15 days in pityriasis versicolor
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Open phase treatment with itraconazole (100 mg once daily) for 15 days
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 110
Study: 505491

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (1 gram every 4 hours up to 21 days)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 31400046

Group type: EXPERIMENTAL
Intervention: Low-dose meloxicam (0.025 mg/kg/day PO)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Phenoxybenzamine and alprazolam
Number of subjects: 51
Study: 29211013

Group type: EXPERIMENTAL
Intervention: Cenerimod 1 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cenerimod 0.5, 1, 2, or 4 mg (once daily for 35 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cenerimod 25 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cenerimod >1 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cenerimod ≥10 mg
Number of subjects: 100
Study: 25510210

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (DX)
Number of subjects: 66

Group type: COMPARATOR
Intervention: High-dosage betahistine (144mg/day)
Number of subjects: 66
Study: 23448592

Group type: EXPERIMENTAL
Intervention: 10 doses of mupirocin (twice daily for 5 days)
Number of subjects: 101

Group type: COMPARATOR
Intervention: 6 doses of mupirocin (twice daily for 3 days or thrice daily for 2 days)
Number of subjects: 101
Study: 21702402

Group type: EXPERIMENTAL
Intervention: Pilocarpine 5 mg twice daily
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Pilocarpine 5 mg four times daily
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Pilocarpine (both doses)
Number of subjects: 201
Study: 19318991

Group type: EXPERIMENTAL
Intervention: 14-month treatment for ADHD
Number of subjects: 436

Group type: COMPARATOR
Intervention: MTA participants
Number of subjects: 436
Study: 17520154

Group type: EXPERIMENTAL
Intervention: 1% adenosine-containing dissolvable film, applied twice daily for three weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% adenosine-containing dissolvable film, applied twice daily for eight weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 15876617

Group type: EXPERIMENTAL
Intervention: Patients with Parkinson's disease
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy elderly subjects
Number of subjects: 21
Study: 12182690

Group type: EXPERIMENTAL
Intervention: ER felodipine 5 mg once daily for 2 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: ER felodipine 10 mg/day for 2 weeks in non-responders
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: ER felodipine 5 mg and 10 mg/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: ER felodipine 5 to 10 mg/day
Number of subjects: 35
Study: 9838913

Group type: EXPERIMENTAL
Intervention: 30-minute drip infusion of granisetron (40 micrograms/kg with 100 ml saline)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 30-second injection of granisetron (40 micrograms/kg with 10 ml saline)
Number of subjects: 20
Study: 7528850

Group type: EXPERIMENTAL
Intervention: Ajmaline (1 mg/kg as bolus followed by infusion of 15 micrograms/kg/min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propafenone (2 mg/kg, followed by infusion of 30 micrograms/kg/min)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ajmaline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 40
Study: 2673619

Group type: EXPERIMENTAL
Intervention: Whole-bowel irrigation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Activated charcoal in sorbitol
Number of subjects: 10
Study: 1251169

Group type: EXPERIMENTAL
Intervention: Liquid soap containing 0.04% phenylmercuric borate
Number of subjects: 128

Group type: COMPARATOR
Intervention: Soap containing only hexachlorophene (Control)
Number of subjects: 128
Study: 28195979

Group type: EXPERIMENTAL
Intervention: Short Interval (SI) - 2 sets of 22 intervals of 10-second runs at 95% VIFT
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Long Interval (LI) - 5 sets of 3-minute intervals at 85% VIFT
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both SI and LI
Number of subjects: 18
Study: 28606845

Group type: EXPERIMENTAL
Intervention: H pylori screening and eradication
Number of subjects: 20011

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20011
Study: 25194639

Group type: EXPERIMENTAL
Intervention: Anger rumination
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Depressive rumination
Number of subjects: 120

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 120
Study: 24024322

Group type: EXPERIMENTAL
Intervention: Xiao Pi‐II (100 mL, t.d.s., ante cibum)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Mosapride (5 mg, t.d.s., ante cibum)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Xiao Pi‐II
Number of subjects: 180

Group type: COMPARATOR
Intervention: Mosapride
Number of subjects: 180
Study: 22166314

Group type: EXPERIMENTAL
Intervention: Surgery with curative intent (272 patients, 82.9%)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Preoperative endoluminal ultrasound (EUS)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Gastrectomy
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Postoperative outcomes
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 328
Study: 18202180

Group type: EXPERIMENTAL
Intervention: sCAX1 carrots
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control carrots
Number of subjects: 30
Study: 16611279

Group type: EXPERIMENTAL
Intervention: Tenatoprazole 40 mg fasting at 7.00 AM
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tenatoprazole 40 mg fasting at 7.00 PM
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tenatoprazole 40 mg fed at 9.30 PM
Number of subjects: 12